CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools

Blood

Volumn 113, Issue 20, 2009, Pages 4955-4962

  Sathyanarayana, Pradeep ^a   Houde, Estelle ^a   Marshall, Deborah ^b   Volk, Amy ^b   Makropoulos, Dorie ^b   Emerson, Christine ^a   Pradeep, Anamika ^a   Bugelski, Peter J ^b   Wojchowski, Don M ^a  

^a Maine Medical Center Research Institute   (United States)

^b CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD71 ANTIGEN; FLUOROURACIL; HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PHOSPHOPROTEIN; PROTEIN CNTO 530; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; ANTIANEMIC AGENT; CNTO 530; DRUG DERIVATIVE; ERYTHROPOIETIN;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; DRUG ACTIVITY; DRUG HALF LIFE; ERYTHROBLAST; ERYTHROCYTE; ERYTHROID CELL; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RETICULOCYTE; SIGNAL TRANSDUCTION; STEADY STATE; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CELL COUNT; CELL CULTURE; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; ERYTHROPOIESIS; MOLECULAR MIMICRY; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANEMIA; ANIMALS; BONE MARROW CELLS; CELL COUNT; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; ERYTHROBLASTS; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; HEMATINICS; MICE; MICE, INBRED C57BL; MOLECULAR MIMICRY; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 66549127370     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-172320     Document Type: Article

References (55)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73-78.
2. Robinson DM, Easthope SE. Darbepoetin alfa: its use in anemia associated with chronic kidney disease. BioDrugs. 2005;19:327-343.
3. Livnah O, Stura EA, Johnson DL, et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science. 1996;273:464-471. (Pubitemid 26286442)
4. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999;283:987-990. (Pubitemid 29100256)
5. Um M, Gross AW, Lodish HF. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal. 2007;19:634-645.
6. Scott CL, Robb L, Papaevangeliou B, Mansfield R, Nicola NA, Begley CG. Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor. Blood. 2000;96:1588-1590.
7. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005;293:90-95.
8. Yang CW, Li C, Jung JY, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 2003;17:1754-1755.
9. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112:999-1007. (Pubitemid 38056315)
10. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 2001;412:641-647. (Pubitemid 32772276)
11. Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med. 2002;8:718-724. (Pubitemid 34778725)
12. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31:290-299. (Pubitemid 36407605)
13. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392-2395. (Pubitemid 29501473)
14. Gross AW, Lodish HF. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem. 2006;281:2024-2032.
15. Sytkowski AJ, Lunn ED, Risinger MA, Davis KL. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem. 1999;274:24773-24778. (Pubitemid 129529364)
16. Sytkowski AJ, Lunn ED, Davis KL, Feldman L, Siekman S. Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci U S A. 1998;95:1184-1188. (Pubitemid 28124933)
17. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4:436-440.
18. Topf JM. CERA: third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother. 2008;9:839-849.
19. Liu Z, Stoll VS, Devries PJ, et al. A potent erythropoietin-mimicking human antibody interacts through a novel binding site. Blood. 2007;110:2408-2413. (Pubitemid 47523161)
20. Bernhardt WM, Warnecke C, Willam C, Tanaka T, Wiesener MS, Eckardt KU. Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol. 2007;435:221-245.
21. Hsieh MM, Linde NS, Wynter A, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood. 2007;110:2140-2147. (Pubitemid 47443933)
22. Johnson DL, Farrell FX, Barbone FP, et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry. 1998;37:3699-3710.
23. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 1996;273:458-464. (Pubitemid 26286441)
24. Wrighton NC, Balasubramanian P, Barbone FP, et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat Biotechnol. 1997;15:1261-1265. (Pubitemid 27465136)
25. Menon MP, Karur V, Bogacheva O, Bogachev O, Cuetara B, Wojchowski DM. Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. J Clin Invest. 2006;116:683-694. (Pubitemid 43326877)
26. Bugelski PJ, Nesspor T, Volk A, et al. Pharmacodynamics of recombinant human erythropoietin in murine bone marrow. Pharm Res. 2008;25:369-378. (Pubitemid 351257974)
27. Bugelski PJ, Capocasale RJ, Makropoulos D, et al. CNTO 530: molecular pharmacology in human UT-7(EPO) cells and pharmacokinetics and pharmacodynamics in mice. J Biotechnol. 2008;134:171-180.
28. Hartley C, Elliott S, Begley CG, et al. Kinetics of haematopoietic recovery after dose-intensive chemo/radiotherapy in mice: optimized erythroid support with darbepoetin alpha. Br J Haematol. 2003;122:623-636. (Pubitemid 36995217)
29. Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant. 2001;16(suppl 3):14-21. (Pubitemid 32591160)
30. Salmonson T, Danielson BG, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol. 1990;29:709-713. (Pubitemid 20183670)
31. Fang J, Menon M, Kapelle W, et al. EPO modulation of cell-cycle regulatory genes, and cell division, in primary bone marrow erythroblasts. Blood. 2007;110:2361-2370. (Pubitemid 47523156)
32. Sathyanarayana P, Dev A, Fang J, et al. EPO receptor circuits for primary erythroblast survival. Blood. 2008;111:5390-5399.
33. Bowen D, Ehmer B, Neubert P, Lewis T, Jacobs A. The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis. Exp Hematol. 1991;19:613-616.
34. Sathyanarayana P, Menon MP, Bogacheva O, et al. Erythropoietin modulation of podocalyxin and a proposed erythroblast niche. Blood. 2007;110:509-518.
35. Arvind Dev JF, McCrann D, Emerson C, et al. Non-redundant roles for an Epo/EpoR/STAT5 regulated intracellular Serpin, Serpina-3G, during Epo- and anemia-induced erythropoiesis [abstract]. Blood. (ASH Annual Meeting Abstracts). 2008; Abstract 894.
36. Bouman-Thio E, Franson K, Miller B, et al. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J Clin Pharmacol. 2008;48:1197-1207.
37. Komatsu N, Yamamoto M, Fujita H, et al. Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. Blood. 1993;82:456-464. (Pubitemid 23206108)
38. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110:177-189. (Pubitemid 34876546)
39. Yonezawa K, Tokunaga C, Oshiro N, Yoshino K. Raptor, a binding partner of target of rapamycin. Biochem Biophys Res Commun. 2004;313:437-441. (Pubitemid 37543605)
40. Pullen N, Dennis PB, Andjelkovic M, et al. Phosphorylation and activation of p70s6k by PDK1. Science. 1998;279:707-710.
41. Romanelli A, Martin KA, Toker A, Blenis J. p70 S6 kinase is regulated by protein kinase Czeta and participates in a phosphoinositide 3-kinase-regulated signalling complex. Mol Cell Biol. 1999;19:2921-2928. (Pubitemid 29144537)
42. Ruffolo SC, Forsell PK, Yuan X, et al. Basal activation of p70S6K results in adipose-specific insulin resistance in protein-tyrosine phosphatase 1B-/- mice. J Biol Chem. 2007;282:30423-30433. (Pubitemid 350035220)
43. Bielinski VA, Mumby MC. Functional analysis of the PP2A subfamily of protein phosphatases in regulating Drosophila S6 kinase. Exp Cell Res. 2007;313:3117-3126.
44. Wang ML, Panasyuk G, Gwalter J, et al. Regulation of ribosomal protein S6 kinases by ubiquitination. Biochem Biophys Res Commun. 2008;369:382-387.
45. Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci. 2006;31:342-348. (Pubitemid 43903237)
46. Menon MP, Fang J, Wojchowski DM. Core erythropoietin receptor signals for late erythroblast development. Blood. 2006;107:2662-2672.
47. Seubert N, Royer Y, Staerk J, et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell. 2003;12:1239-1250. (Pubitemid 37487931)
48. Furness SG, McNagny K. Beyond mere markers: functions for CD34 family of sialomucins in hematopoiesis. Immunol Res. 2006;34:13-32. (Pubitemid 43780374)
49. Doyonnas R, Kershaw DB, Duhme C, et al. Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med. 2001;194:13-27. (Pubitemid 32660434)
50. Doyonnas R, Nielsen JS, Chelliah S, et al. Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells. Blood. 2005;105:4170-4178. (Pubitemid 40720759)
51. Sizemore S, Cicek M, Sizemore N, Ng KP, Casey G. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res. 2007;67:6183-6191. (Pubitemid 47037499)
52. Kelley TW, Huntsman D, McNagny KM, Roskelley CD, Hsi ED. Podocalyxin: a marker of blasts in acute leukemia. Am J Clin Pathol. 2005;124:134-142.
53. Crowley JE, Treml LS, Stadanlick JE, Carpenter E, Cancro MP. Homeostatic niche specification among naive and activated B cells: a growing role for the BLyS family of receptors and ligands. Semin Immunol. 2005;17:193-199. (Pubitemid 40488978)
54. Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol. 2007;7:144-154. (Pubitemid 46178275)
55. Chasis JA. Erythroblastic islands: specialized microenvironmental niches for erythropoiesis. Curr Opin Hematol. 2006;13:137-141.